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Antibody persistence 22 months after vaccination of ado-
lescents with the Novartis investigational meningococcal
ACWY-CRM197 conjugate vaccine or Menactra®
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Dull 1
1 Novartis Vaccines and Diagnostics, Cambridge, MA, USA
2 Novartis Vaccines and Diagnostics, Sienna, Italy
3 Novartis Vaccines and Diagnostics, Marburg, Germany
Background: Improved primary response, induction of
immunologic memory and antibody persistence are key
attributes of conjugate vaccines. We have previously pre-
sented immunogenicity data one month post-vaccination
from a phase III, randomized, observerblind comparative
study of an investigational meningococcal ACWY-CRM197
conjugate vaccine (MenACWY-CRM, Novartis) or Menactra®
(MCV-4, Sanoﬁ Pasteur). Data from approximately two years
post-vaccination in an ongoing long-term study of persis-
tence of bactericidal antibodies are now available.
Methods: Subjects, who were aged 11-18 years when
enrolled into the parent study, were approached for enroll-
ment. Age-matched meningococcal vaccine-naïve subjects
were enrolled to serve as additional controls. The primary
objective was to assess the persistence of immune response
for each serogroup using a serum bactericidal assay with
human complement (hSBA), expressed as the proportions
of subjects with a titer ≥1:8 and Geometric Mean Titers
(GMTs).
Results: At a median of 22 months post vaccination,
278 MenACWY-CRM and 191 MCV-4 subjects, plus 128 naïve
controls were enrolled. For serogroups A, C, W and Y respec-
tively, the proportions of subjects with hSBA ≥1:8 were: 36%,
62%, 84%, and 67% for MenACWYCRM; 25%, 58%, 74%, 54% for
MCV-4; and 5%, 42%, 51% and 40% for the naïve controls. Sim-
ilarly hSBA GMTs for serogroups A, C, W and Y, respectively,
were: 5.3, 10.0, 18.0 and 12.0 for MenACWY; 3.6, 8.7, 14,
and 7.9 for MCV-4; and 2.4, 6.0, 7.8 and 5.1 for the con-
trols. Compared with MCV-4 recipients, the proportions of
MenACWY-CRM vaccinees with hSBA ≥1:8 was signiﬁcantly
higher for serogroups A, W and Y; GMTs were signiﬁcantly
higher for serogroups A and Y. Compared with naïve con-
trols, GMTs were signiﬁcantly higher for MenACWY-CRM for
all four serogroups.
Conclusion: A majority of adolescents maintain bacte-
ricidal antibody titers above 1:8 against meningococcal
serogroups C,W and Y two years after receiving either conju-
gate vaccine although more of the MenACWY-CRM vaccinees
still had protective antibody titers against serogroups A, W,
and Y than those who received MCV-4.
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NOW ESSENTIALS — A novel algorithm for informed
accine-related decision-making in developing countries
.L. Mathew
Post Graduate Institute of Medical Education and Research,
handigarh, India
Background: In most developing countries, vaccine-
elated decisions are seldom evidencebased and health-care
takeholders (physicians/policy-makers/patients) usually do
ot have access to locally relevant health technology
ssessment (HTA), in contrast to developed countries.
he objective was to develop a decision-making algorithm
acilitating informed vaccinerelated decisions by various
takeholders in developing countries, using available infor-
ation from literature.
Methods: KNOW ESSENTIALS is an acronym for 13 com-
onents to be evaluated for informed vaccine-related
ecisions. The ﬁrst three deﬁning criteria (acronym KNOW)
re establishment of (i)Knowledge of need (KN) for the vac-
ine, (ii)Outcome of interest (O), (iii) Which stake-holder is
nvolved (W). Subsequent components should be evaluated
nly when all three are clear. The other criteria (acronym
SSENTIALS) are: (iv)Evidence of effectiveness and/or efﬁ-
acy, (v)Safety, (vi)Social quotient (consumer acceptability
nd ethical/legal/moral propriety), (vii)Economic issues
iz cost and cost-effectiveness, (viii)Novelty (newness),
ix)Time to outcome of interest, (x)Integration with existing
ervices/facilities, (xi)Alternate options, (xii)Likely impact
f not choosing the intervention, and (xiii)Sustainability.
ased on local and/or external data/information from lit-
rature, each of these is categorised as Red (unfavourable),
reen (favourable), Yellow (insufﬁcient/unclear data) or
hite (notapplicable). The basis for colour coding has been
laborately deﬁned for each criterion to exclude subjectiv-
ty; but is not presented here for lack of space. Criteria
iv) to (vii) are mandatory criteria and stake-holders should
roceed only if all are Green.
Table 1 shows practical application of the algorithm for
currently relevant, challenging decision: whether India
hould consider universal human papillomavirus(HPV) vac-
ination.
Results: The algorithm can be applied by multiple
take-holders (policymakers/physicians/patients/health-
are payers) to make objective decisions for their setting
ased on explicit criteria; thus saving time and cost. It
nables each stake-holder to arrive at an informed decision
ppropriate for them. Pilot testing considering various
accines as well as different stake-holders suggests that
t facilitates objective, reproducible, and transparent
ecision-making. A randomized trial comparing it against
ormal HTA is planned.Conclusion: KNOW ESSENTIALS is a practical algorithm
acilitating informed vaccinerelated decisions by various
ealth-care stake-holders in developing country settings.
oi:10.1016/j.ijid.2010.02.612
